These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38143567)

  • 41. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis.
    Matsushita T; Mizumaki K; Kano M; Yagi N; Tennichi M; Takeuchi A; Okamoto Y; Hamaguchi Y; Murakami A; Hasegawa M; Kuwana M; Fujimoto M; Takehara K
    Br J Dermatol; 2017 Feb; 176(2):395-402. PubMed ID: 27452897
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Case Report: Extracorporeal Membrane Oxgenation for Rapidly Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis in a Post-partum Woman.
    Gu Q; Diao M; Hu W; Huang M; Zhu Y
    Front Med (Lausanne); 2021; 8():742823. PubMed ID: 34660647
    [No Abstract]   [Full Text] [Related]  

  • 43. [Value of serum YKL-40 in the diagnosis of anti-MDA5-positive patients with dermatomyositis complicated with severe pulmonary injury].
    Zhang PL; Yang HX; Zhang LN; Ge YP; Peng QL; Wang GC; Lu X
    Beijing Da Xue Xue Bao Yi Xue Ban; 2021 Dec; 53(6):1055-1060. PubMed ID: 34916681
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Disease characteristics and clinical outcomes of adults and children with anti-MDA-5 antibody-associated myositis: a prospective observational bicentric study.
    Dunga SK; Kavadichanda C; Gupta L; Naveen R; Agarwal V; Negi VS
    Rheumatol Int; 2022 Jul; 42(7):1155-1165. PubMed ID: 34050793
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic evaluation of serum osteopontin in patients with anti-MDA5 antibody-positive dermatomyositis associated interstitial lung disease.
    Gao Y; Zhao Q; Xie M; Yan X; Li Y; Zhang X; Wu H; Dai J; Cao M; Cai H
    Cytokine; 2020 Nov; 135():155209. PubMed ID: 32738770
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review.
    Huang K; Vinik O; Shojania K; Yeung J; Shupak R; Nimmo M; Avina-Zubieta JA
    Rheumatol Int; 2019 Nov; 39(11):1971-1981. PubMed ID: 31375890
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Slowly progressive interstitial lung disease preceding typical dermatomyositis symptoms in anti-melanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis.
    Isono T; Nakajima H; Takano K; Kobayashi Y; Kawabata Y; Shimizu Y; Takayanagi N
    Respir Med Case Rep; 2021; 34():101491. PubMed ID: 34381685
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Management of Myositis-Associated Interstitial Lung Disease.
    Fujisawa T
    Medicina (Kaunas); 2021 Apr; 57(4):. PubMed ID: 33916864
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lung histopathological pattern in a survivor with rapidly progressive interstitial lung disease and anti-melanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis.
    Suzuki A; Kondoh Y; Taniguchi H; Tabata K; Kimura T; Kataoka K; Ono K; Hashisako M; Fukuoka J
    Respir Med Case Rep; 2016; 19():5-8. PubMed ID: 27354955
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Comparison of clinical and immunological features between clinically amyopathic dermatomyositis and typical dermatomyositis].
    Gan YZ; Li YH; Zhang LH; Ma L; He WW; Jin YB; An Y; Li ZG; Ye H
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Dec; 52(6):1001-1008. PubMed ID: 33331305
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis.
    Ida T; Furuta S; Takayama A; Tamura J; Hayashi Y; Abe K; Kurihara S; Ishikawa J; Iwamoto T; Ikeda K; Suzuki K; Nakajima H
    RMD Open; 2023 Jan; 9(1):. PubMed ID: 36593080
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anti-MDA5 antibody-positive hypomyopathic dermatomyositis complicated with pneumomediastinum.
    Yashiro M; Asano T; Sato S; Kobayashi H; Watanabe H; Miyata M; Migita K
    Fukushima J Med Sci; 2018; 64(2):89-94. PubMed ID: 30158335
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Erythematous auricular papules in the fatal cases of anti-MDA5 antibody-positive interstitial lung disease.
    Intapiboon P; Siripaitoon B
    Respir Med Case Rep; 2020; 31():101299. PubMed ID: 33294359
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis.
    Sakamoto S; Okamoto M; Kaieda S; Fujimoto K; Nagata S; Tominaga M; Nakamura M; Zaizen Y; Nouno T; Koga T; Kawayama T; Kuwana M; Ida H; Hoshino T
    Respir Investig; 2018 Nov; 56(6):464-472. PubMed ID: 30150008
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis.
    Kobayashi N; Takezaki S; Kobayashi I; Iwata N; Mori M; Nagai K; Nakano N; Miyoshi M; Kinjo N; Murata T; Masunaga K; Umebayashi H; Imagawa T; Agematsu K; Sato S; Kuwana M; Yamada M; Takei S; Yokota S; Koike K; Ariga T
    Rheumatology (Oxford); 2015 May; 54(5):784-91. PubMed ID: 25288783
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy.
    Abe Y; Kusaoi M; Tada K; Yamaji K; Tamura N
    Rheumatology (Oxford); 2020 Apr; 59(4):767-771. PubMed ID: 31504956
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical Features of Anti-MDA5 Antibody-positive Rapidly Progressive Interstitial Lung Disease without Signs of Dermatomyositis.
    Sakamoto N; Ishimoto H; Nakashima S; Yura H; Miyamura T; Okuno D; Hara A; Kitazaki T; Kakugawa T; Ishimatsu Y; Satoh M; Mukae H
    Intern Med; 2019 Mar; 58(6):837-841. PubMed ID: 30449789
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Soluble CD206 levels correlate with disease deterioration and predict prognosis of anti-MDA5 antibody-positive dermatomyositis related interstitial lung disease.
    Li Y; Liu X; Tian M; Zou R; Gao Y; Huang M; Zhou K; Cao M; Cai H
    Clin Respir J; 2023 Jun; 17(6):507-515. PubMed ID: 37041007
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies.
    Yamaguchi K; Yamaguchi A; Kashiwagi C; Sawada Y; Taguchi K; Umetsu K; Oshima K; Uchida M; Suzuki M; Kono S; Takemura M; Masubuchi H; Kitahara S; Hara K; Maeno T; Motegi SI; Muro Y; Sakairi T; Hisada T; Kurabayashi M
    Respir Med; 2018 Jul; 140():1-5. PubMed ID: 29957268
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Different Multivariable Risk Factors for Rapid Progressive Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis and Anti-Synthetase Syndrome.
    Zuo Y; Ye L; Chen F; Shen Y; Lu X; Wang G; Shu X
    Front Immunol; 2022; 13():845988. PubMed ID: 35320936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.